[Drug-induced parkinson syndromes].
Identifieur interne : 001807 ( PubMed/Checkpoint ); précédent : 001806; suivant : 001808[Drug-induced parkinson syndromes].
Auteurs : Nhan Nguyen [France] ; Vincent Pradel ; Joëlle Micallef ; Jean-Louis Montastruc ; Olivier BlinSource :
- Therapie [ 0040-5957 ]
English descriptors
- KwdEn :
- Anticonvulsants (adverse effects), Antidepressive Agents (adverse effects), Antipsychotic Agents (adverse effects), Calcium Channel Blockers (adverse effects), Humans, Lithium (adverse effects), Parkinson Disease, Secondary (chemically induced), Parkinson Disease, Secondary (diagnosis), Parkinson Disease, Secondary (epidemiology), Parkinson Disease, Secondary (physiopathology), Serotonin Uptake Inhibitors (adverse effects), Valproic Acid (adverse effects).
- MESH :
- chemical , adverse effects : Anticonvulsants, Antidepressive Agents, Antipsychotic Agents, Calcium Channel Blockers, Lithium, Serotonin Uptake Inhibitors, Valproic Acid.
- chemically induced : Parkinson Disease, Secondary.
- diagnosis : Parkinson Disease, Secondary.
- epidemiology : Parkinson Disease, Secondary.
- physiopathology : Parkinson Disease, Secondary.
- Humans.
Abstract
Parkinsonism is defined by the association of akinesia with one of the following symptoms: extrapyramidal rigidity, tremor at rest, or postural instability. A drug-induced aetiology must always be suspected when parkinsonian symptoms appear, or increase in a patient receiving drug treatment. Indeed drug-induced is the more frequent aetiology of secondary parkinsonism. The main treatments involved are antipsychotic and other neuroleptic drugs (accounting for up to two-thirds of drug-induced parkinsonism), and calcium-channel entry blockers. The risk associated with antipsychotics is often dose dependent and related to dopamine D2 striatal receptor occupancy induced by the antipsychotic drug. This risk is inferior for the second generation antipsychotics. The other treatments more rarely involved are antidepressants (tricyclic and selective serotonin reuptake inhibitors), lithium, valproic acid, and others. The main criterium for imputability is chronological, regression of symptoms being observed in 40-74% of cases, after a mean delay of 3 months from cessation of treatment. However, 15% of cases persist after drug withdrawal, leading to a diagnosis of underlying idiopathic Parkinson's disease.
PubMed: 15199676
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:15199676Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Drug-induced parkinson syndromes].</title><author><name sortKey="Nguyen, Nhan" sort="Nguyen, Nhan" uniqKey="Nguyen N" first="Nhan" last="Nguyen">Nhan Nguyen</name><affiliation wicri:level="4"><nlm:affiliation>CPCET et Pharmacologie Clinique, Institut de Neurosciences Physiologiques et Cognitives, Faculté de Médecine, FRE 2109 CNRS-Université de la Méditerranée, Assistance Publique Hôpitaux de Marseille, Hôpital de la Timone, Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CPCET et Pharmacologie Clinique, Institut de Neurosciences Physiologiques et Cognitives, Faculté de Médecine, FRE 2109 CNRS-Université de la Méditerranée, Assistance Publique Hôpitaux de Marseille, Hôpital de la Timone, Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName><orgName type="university">Université de la Méditerranée</orgName></affiliation></author><author><name sortKey="Pradel, Vincent" sort="Pradel, Vincent" uniqKey="Pradel V" first="Vincent" last="Pradel">Vincent Pradel</name></author><author><name sortKey="Micallef, Joelle" sort="Micallef, Joelle" uniqKey="Micallef J" first="Joëlle" last="Micallef">Joëlle Micallef</name></author><author><name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name></author><author><name sortKey="Blin, Olivier" sort="Blin, Olivier" uniqKey="Blin O" first="Olivier" last="Blin">Olivier Blin</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="????"><PubDate><MedlineDate>2004 Jan-Feb</MedlineDate></PubDate></date><idno type="RBID">pubmed:15199676</idno><idno type="pmid">15199676</idno><idno type="wicri:Area/PubMed/Corpus">001053</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001053</idno><idno type="wicri:Area/PubMed/Curation">001012</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001012</idno><idno type="wicri:Area/PubMed/Checkpoint">001012</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001012</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Drug-induced parkinson syndromes].</title><author><name sortKey="Nguyen, Nhan" sort="Nguyen, Nhan" uniqKey="Nguyen N" first="Nhan" last="Nguyen">Nhan Nguyen</name><affiliation wicri:level="4"><nlm:affiliation>CPCET et Pharmacologie Clinique, Institut de Neurosciences Physiologiques et Cognitives, Faculté de Médecine, FRE 2109 CNRS-Université de la Méditerranée, Assistance Publique Hôpitaux de Marseille, Hôpital de la Timone, Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CPCET et Pharmacologie Clinique, Institut de Neurosciences Physiologiques et Cognitives, Faculté de Médecine, FRE 2109 CNRS-Université de la Méditerranée, Assistance Publique Hôpitaux de Marseille, Hôpital de la Timone, Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName><orgName type="university">Université de la Méditerranée</orgName></affiliation></author><author><name sortKey="Pradel, Vincent" sort="Pradel, Vincent" uniqKey="Pradel V" first="Vincent" last="Pradel">Vincent Pradel</name></author><author><name sortKey="Micallef, Joelle" sort="Micallef, Joelle" uniqKey="Micallef J" first="Joëlle" last="Micallef">Joëlle Micallef</name></author><author><name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name></author><author><name sortKey="Blin, Olivier" sort="Blin, Olivier" uniqKey="Blin O" first="Olivier" last="Blin">Olivier Blin</name></author></analytic><series><title level="j">Therapie</title><idno type="ISSN">0040-5957</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anticonvulsants (adverse effects)</term><term>Antidepressive Agents (adverse effects)</term><term>Antipsychotic Agents (adverse effects)</term><term>Calcium Channel Blockers (adverse effects)</term><term>Humans</term><term>Lithium (adverse effects)</term><term>Parkinson Disease, Secondary (chemically induced)</term><term>Parkinson Disease, Secondary (diagnosis)</term><term>Parkinson Disease, Secondary (epidemiology)</term><term>Parkinson Disease, Secondary (physiopathology)</term><term>Serotonin Uptake Inhibitors (adverse effects)</term><term>Valproic Acid (adverse effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anticonvulsants</term><term>Antidepressive Agents</term><term>Antipsychotic Agents</term><term>Calcium Channel Blockers</term><term>Lithium</term><term>Serotonin Uptake Inhibitors</term><term>Valproic Acid</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinsonism is defined by the association of akinesia with one of the following symptoms: extrapyramidal rigidity, tremor at rest, or postural instability. A drug-induced aetiology must always be suspected when parkinsonian symptoms appear, or increase in a patient receiving drug treatment. Indeed drug-induced is the more frequent aetiology of secondary parkinsonism. The main treatments involved are antipsychotic and other neuroleptic drugs (accounting for up to two-thirds of drug-induced parkinsonism), and calcium-channel entry blockers. The risk associated with antipsychotics is often dose dependent and related to dopamine D2 striatal receptor occupancy induced by the antipsychotic drug. This risk is inferior for the second generation antipsychotics. The other treatments more rarely involved are antidepressants (tricyclic and selective serotonin reuptake inhibitors), lithium, valproic acid, and others. The main criterium for imputability is chronological, regression of symptoms being observed in 40-74% of cases, after a mean delay of 3 months from cessation of treatment. However, 15% of cases persist after drug withdrawal, leading to a diagnosis of underlying idiopathic Parkinson's disease.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15199676</PMID><DateCreated><Year>2004</Year><Month>06</Month><Day>17</Day></DateCreated><DateCompleted><Year>2004</Year><Month>07</Month><Day>21</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0040-5957</ISSN><JournalIssue CitedMedium="Print"><Volume>59</Volume><Issue>1</Issue><PubDate><MedlineDate>2004 Jan-Feb</MedlineDate></PubDate></JournalIssue><Title>Therapie</Title><ISOAbbreviation>Therapie</ISOAbbreviation></Journal><ArticleTitle>[Drug-induced parkinson syndromes].</ArticleTitle><Pagination><MedlinePgn>105-12</MedlinePgn></Pagination><Abstract><AbstractText>Parkinsonism is defined by the association of akinesia with one of the following symptoms: extrapyramidal rigidity, tremor at rest, or postural instability. A drug-induced aetiology must always be suspected when parkinsonian symptoms appear, or increase in a patient receiving drug treatment. Indeed drug-induced is the more frequent aetiology of secondary parkinsonism. The main treatments involved are antipsychotic and other neuroleptic drugs (accounting for up to two-thirds of drug-induced parkinsonism), and calcium-channel entry blockers. The risk associated with antipsychotics is often dose dependent and related to dopamine D2 striatal receptor occupancy induced by the antipsychotic drug. This risk is inferior for the second generation antipsychotics. The other treatments more rarely involved are antidepressants (tricyclic and selective serotonin reuptake inhibitors), lithium, valproic acid, and others. The main criterium for imputability is chronological, regression of symptoms being observed in 40-74% of cases, after a mean delay of 3 months from cessation of treatment. However, 15% of cases persist after drug withdrawal, leading to a diagnosis of underlying idiopathic Parkinson's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Nhan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>CPCET et Pharmacologie Clinique, Institut de Neurosciences Physiologiques et Cognitives, Faculté de Médecine, FRE 2109 CNRS-Université de la Méditerranée, Assistance Publique Hôpitaux de Marseille, Hôpital de la Timone, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pradel</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Micallef</LastName><ForeName>Joëlle</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Montastruc</LastName><ForeName>Jean-Louis</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Blin</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Les syndromes parkinsoniens médicamenteux.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Therapie</MedlineTA><NlmUniqueID>0420544</NlmUniqueID><ISSNLinking>0040-5957</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002121">Calcium Channel Blockers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017367">Serotonin Uptake Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002121" MajorTopicYN="N">Calcium Channel Blockers</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010302" MajorTopicYN="N">Parkinson Disease, Secondary</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017367" MajorTopicYN="N">Serotonin Uptake Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>56</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>6</Month><Day>18</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>7</Month><Day>22</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>6</Month><Day>18</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15199676</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Provence-Alpes-Côte d'Azur</li></region><settlement><li>Marseille</li></settlement><orgName><li>Université de la Méditerranée</li></orgName></list><tree><noCountry><name sortKey="Blin, Olivier" sort="Blin, Olivier" uniqKey="Blin O" first="Olivier" last="Blin">Olivier Blin</name><name sortKey="Micallef, Joelle" sort="Micallef, Joelle" uniqKey="Micallef J" first="Joëlle" last="Micallef">Joëlle Micallef</name><name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name><name sortKey="Pradel, Vincent" sort="Pradel, Vincent" uniqKey="Pradel V" first="Vincent" last="Pradel">Vincent Pradel</name></noCountry><country name="France"><region name="Provence-Alpes-Côte d'Azur"><name sortKey="Nguyen, Nhan" sort="Nguyen, Nhan" uniqKey="Nguyen N" first="Nhan" last="Nguyen">Nhan Nguyen</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001807 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001807 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:15199676
|texte= [Drug-induced parkinson syndromes].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:15199676" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |